To keep the cancer from recurring, patients must take maintenance chemotherapy pills for as long as a year.
Some of these were only found in normozoospermic controls (N = 21), at most once per group (N = 58) or not in controls (N = 14, recurring, patient-specific CNVs).
The recurring, patient-specific and private, sex-chromosomal CNVs as well as those associated with SCOS are candidates for further, larger case-control and re-sequencing studies.
All the recurring, patient-specific and private, sex-chromosomal CNVs as well as the CNVs associated with SCOS described herein are candidates deserving further detailed analyses in larger patient and control groups as well as other populations.
Therefore, three subsets of distantly recurring patients (to soft tissue, bone, lung or liver or CNS) were analysed.
In the case of recurring patients, the time between the first and second operation varied between 2 and 8 years.
The number of recurring patients and the number of deceased patients at 5 and 10 years of follow-up are reported in Table 2. Hormone receptor status was obtained for 81.2% of tumours (Table 1).
Parameters describing disease progression were preliminarily estimated through calibration to match five-year disease-free survival, overall survival at years 1 5, and proportion of recurring patients undergoing curative salvage surgery from one arm of a published randomized trial.
On the basis of this, a phase II study of oral gimatecan in progressing or recurring patients with advanced epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes, was initiated in Europe.
Three subsets of distantly recurring patients (to soft tissue, bone and viscera) were analysed and the analysis did not support any evidence of a different hazard shape behaviour according to the different events.
